Covered recipient · General Payments record
WAYNE HARPER
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$14.65
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $14.65 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $14.65 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
WAYNE HARPER
NPI 1376538926 · CMS profile ID 197757
Allopathic & Osteopathic Physicians / Internal Medicine
RALEIGH, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- WAYNE HARPER, NPI 1376538926, CMS profile ID 197757. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). WAYNE HARPER, NPI 1376538926, CMS profile ID 197757. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- WAYNE HARPER, NPI 1376538926, CMS profile ID 197757, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1376538926?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $14.65 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.65 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997438869 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2023
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2021 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2022 | Principal investigator | $74,594.70 | 18 |
| PY2021 | Principal investigator | $2,376,430.02 | 49 |
| PY2020 | Principal investigator | $3,589,740.22 | 82 |
| PY2019 | Recipient | $9,290.45 | 2 |
| PY2019 | Principal investigator | $696,096.81 | 90 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
92 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,000.00 | 12/19/2019 | Non-covered Recipient Entity Wake Research Associates | HSV15 Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults with Recurrent Genital Herpes Caused by HSV 2 | No dispute reported | 06/30/2026 | 691624977 |
| Principal investigator 1 | PFIZER INC. | $5,377.08 | 12/04/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685371 |
| Principal investigator 1 | PFIZER INC. | $866.78 | 11/28/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 671668795 |
| Principal investigator 1 | PFIZER INC. | $1,148.56 | 11/28/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 671677079 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,890.00 | 11/19/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685023045 |
| Principal investigator 1 | PFIZER INC. | $204.68 | 11/13/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671663753 |
| Principal investigator 1 | PFIZER INC. | $1,216.10 | 11/07/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671663709 |
| Principal investigator 1 | PFIZER INC. | $550.65 | 11/07/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671663799 |
| Principal investigator 1 | PFIZER INC. | $251.07 | 11/01/2019 | Non-covered Recipient Entity Wake Research Associates LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 671673447 |
| Principal investigator 1 | PFIZER INC. | $1,962.38 | 11/01/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685373 |
| Principal investigator 1 | PFIZER INC. | $841.02 | 11/01/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671686247 |
| Principal investigator 1 | PFIZER INC. | $33,040.61 | 10/22/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671685375 |
| Principal investigator 1 | PFIZER INC. | $2,084.68 | 10/22/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686185 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $812.79 | 10/16/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685023009 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,040.00 | 10/16/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685023019 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,487.62 | 10/16/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685023031 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,890.00 | 10/16/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685023041 |
| Principal investigator 1 | PFIZER INC. | $1,402.25 | 10/10/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671663707 |
| Principal investigator 1 | PFIZER INC. | $552.50 | 10/10/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671663755 |
| Principal investigator 1 | PFIZER INC. | $4,647.25 | 10/08/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686249 |
| Principal investigator 1 | PFIZER INC. | $1,550.77 | 10/03/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671663751 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 10/02/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723475 |
| Principal investigator 1 | PFIZER INC. | $8,769.61 | 10/02/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | A PHASE 3 RANDOMIZED DOUBLE BLIND PLACEBO AND ACTIVECONTROLLED MULTICENTER PARALLELGROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | No dispute reported | 06/30/2026 | 671663801 |
| Recipient | SANOFI PASTEUR INC. | $593.45 | 09/28/2019 | Covered Recipient Physician | Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use | No dispute reported | 06/30/2026 | 691624857 |
| Principal investigator 1 | PFIZER INC. | $5,429.39 | 09/19/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685771 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $126.37 | 09/19/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685020493 |
| Principal investigator 1 | PFIZER INC. | $2,242.72 | 08/27/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671686187 |
| Principal investigator 1 | PFIZER INC. | $235.06 | 08/15/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671663797 |
| Principal investigator 1 | PFIZER INC. | $3,435.76 | 08/03/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685773 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $655.08 | 07/25/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 629914387 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $1,211.28 | 07/25/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 629914389 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $8.39 | 07/25/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 632154875 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $15.52 | 07/25/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 632154879 |
| Principal investigator 1 | PFIZER INC. | $521.17 | 07/17/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671685705 |
| Principal investigator 1 | PFIZER INC. | $13,844.32 | 07/12/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685703 |
| Principal investigator 1 | Novo Nordisk AS | $23.93 | 07/10/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723477 |
| Principal investigator 1 | PFIZER INC. | $3,281.39 | 07/09/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686251 |
| Principal investigator 1 | PFIZER INC. | $8,523.92 | 06/22/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685443 |
| Principal investigator 1 | PFIZER INC. | $4,640.87 | 06/21/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671685441 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,250.00 | 06/21/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685018889 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 06/21/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685018891 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,000.00 | 06/21/2019 | Non-covered Recipient Entity M3 Wake Research, Inc | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 685018895 |
| Principal investigator 1 | PFIZER INC. | $97.50 | 06/19/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 671644875 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $3,047.20 | 06/14/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 | No dispute reported | 06/30/2026 | 691333091 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $97.05 | 06/11/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 | No dispute reported | 06/30/2026 | 691346945 |
| Principal investigator 1 | Novo Nordisk AS | $45.52 | 06/05/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723479 |
| Principal investigator 1 | Novo Nordisk AS | $20.40 | 06/05/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723481 |
| Principal investigator 1 | Novo Nordisk AS | $167.51 | 06/05/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723483 |
| Principal investigator 1 | PFIZER INC. | $24,554.20 | 06/04/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685439 |
| Principal investigator 1 | PFIZER INC. | $11,465.74 | 05/31/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671686191 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $950.00 | 05/29/2019 | Non-covered Recipient Entity M3 WAKE RESEARCH INC | A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations | No dispute reported | 06/30/2026 | 639739555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,000.00 | 05/29/2019 | Non-covered Recipient Entity M3 WAKE RESEARCH INC | A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations | No dispute reported | 06/30/2026 | 639739557 |
| Principal investigator 1 | PFIZER INC. | $200.38 | 05/28/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685635 |
| Principal investigator 1 | PFIZER INC. | $8,338.72 | 05/23/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671685511 |
| Principal investigator 1 | PFIZER INC. | $13,571.38 | 05/23/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686189 |
| Principal investigator 1 | PFIZER INC. | $1,148.56 | 05/22/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 671624219 |
| Principal investigator 1 | PFIZER INC. | $300.57 | 05/14/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685573 |
| Principal investigator 1 | PFIZER INC. | $35,469.16 | 05/07/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685513 |
| Principal investigator 1 | PFIZER INC. | $300.57 | 05/06/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685637 |
| Principal investigator 1 | PFIZER INC. | $16,943.94 | 05/03/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671686119 |
| Principal investigator 1 | Novo Nordisk AS | $20.01 | 04/25/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723485 |
| Principal investigator 1 | Novo Nordisk AS | $20.01 | 04/25/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723487 |
| Principal investigator 1 | PFIZER INC. | $1,148.56 | 04/24/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 671626317 |
| Principal investigator 1 | PFIZER INC. | $8,842.60 | 04/23/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686117 |
| Principal investigator 1 | PFIZER INC. | $271,882.78 | 04/19/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671686115 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $186.00 | 04/17/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. | No dispute reported | 06/30/2026 | 691489853 |
| Principal investigator 1 | PFIZER INC. | $801.52 | 04/15/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685633 |
| Principal investigator 1 | Novo Nordisk AS | $33.35 | 04/11/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723489 |
| Principal investigator 1 | Novo Nordisk AS | $33.35 | 04/11/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723491 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $78,814.44 | 04/10/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 629914391 |
| Principal investigator 1 | Sunovion Pharmaceuticals Inc. | $1,010.23 | 04/10/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | Dasotraline Binge Eating Disorder Extension Study | No dispute reported | 06/30/2026 | 632154883 |
| Principal investigator 1 | PFIZER INC. | $26,527.80 | 04/09/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686193 |
| Principal investigator 1 | PFIZER INC. | $5,700.00 | 04/09/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | No dispute reported | 06/30/2026 | 671686253 |
| Principal investigator 1 | PFIZER INC. | $701.33 | 04/02/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671685701 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $8,838.00 | 03/21/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. | No dispute reported | 06/30/2026 | 691316375 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,161.00 | 03/04/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 | No dispute reported | 06/30/2026 | 691327173 |
| Principal investigator 1 | Flexion Therapeutics, Inc. | $9,000.00 | 03/01/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis | No dispute reported | 06/30/2026 | 705979639 |
| Principal investigator 1 | PFIZER INC. | $7,634.00 | 02/26/2019 | Non-covered Recipient Entity CAROLINA PHASE RESEARCH LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671664727 |
| Principal investigator 1 | PFIZER INC. | $279.04 | 02/20/2019 | Non-covered Recipient Entity Carolina Phase 1 Research LLC | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671618437 |
| Principal investigator 1 | PFIZER INC. | $70.00 | 02/19/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671644943 |
| Principal investigator 1 | PFIZER INC. | $70.00 | 02/19/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 671644945 |
| Principal investigator 1 | PFIZER INC. | $6,512.00 | 02/19/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686255 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,161.00 | 02/15/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 | No dispute reported | 06/30/2026 | 691327169 |
| Principal investigator 1 | Novo Nordisk AS | $18.16 | 02/15/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723493 |
| Principal investigator 1 | Novo Nordisk AS | $63.20 | 02/15/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723495 |
| Principal investigator 1 | Novo Nordisk AS | $178.78 | 02/14/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723497 |
| Recipient | Bio Products Laboratory USA, Inc. | $8,697.00 | 02/08/2019 | Covered Recipient Physician | RIG01 | No dispute reported | 06/30/2026 | 705328153 |
| Principal investigator 1 | PFIZER INC. | $200.38 | 02/05/2019 | Non-covered Recipient Entity M3 Wake Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 671686257 |
| Principal investigator 1 | PFIZER INC. | $97.50 | 02/04/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES LLC | A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS | No dispute reported | 06/30/2026 | 671618193 |
| Principal investigator 1 | Novo Nordisk AS | $18.00 | 01/18/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | NN9536-4376 | No dispute reported | 06/30/2026 | 706723499 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $148.80 | 01/08/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 | No dispute reported | 06/30/2026 | 691489105 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,600.00 | 01/03/2019 | Non-covered Recipient Entity WAKE RESEARCH ASSOCIATES, LLC | A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease PNEU - DAY. | No dispute reported | 06/30/2026 | 691308285 |